Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05201638

Active Not RecruitingPhase 3

Sponsor: Immunic AG

Conditions: Multiple Sclerosis, Relapsing-Remitting

Interventions: IMU-838 tablets, Placebo matching IMU-838 tablets

Countries: United States, Armenia, Bosnia and Herzegovina, Estonia, Germany, India, Peru, Poland

Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Male or female patient (age ≥18 to ≤55 years).
* Patients with an established diagnosis of MS according to 2017 McDonald Criteria.
* Patients with RMS comprising of relapsing remitting MS (RRMS) and active secondary progressive MS, both defined according to Lublin criteria 1996 and 2014.
* Active disease as defined by Lublin 2014 evidenced prior to Screening by:

  1. At least 2 relapses in the last 24 months before randomization, or
  2. At least 1 relapse in the last 12 months before randomization, or
  3. A positive Gd+ MRI scan (brain and/or spine) in the last 12 months prior to randomization.
* Willingness and ability to comply with the protocol.
* Written informed consent given prior to any study-related procedure.

Exclusion Criteria:

* Patients with non-active secondary progressive MS and primary progressive MS.
* Any disease other than MS that may better explain the signs and symptoms, including history of complete transverse myelitis.
* Clinical signs or presence of laboratory findings suggestive for neuromyelitis optica (NMO) spectrum disorders or myelin oligodendrocyte glycoprotein (MOG)-IgG-associated encephalomyelitis
* Any active and uncontrolled coexisting autoimmune disease, other than MS (except for type 1 diabetes mellitus and inflammatory bowel disease)
* Use of experimental/investigational drug (with the exception of COVID-19 vaccines approved by emergency use authorization) and/or participation in drug clinical studies within 6 months prior to Screening
* Previous or current use of MS treatments lifelong, or within a pre-specified time period.
* Use of the pre-specified concomitant medications.
* Clinically significantly abnormal and pre-specified lab values.
* History of chronic systemic infections within 6 months before the date of informed consent.
* Diagnosis or suspected liver function impairment, which may cause fluctuating liver function tests during this study.
* Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis.
* History or clinical diagnosis of gout.
* History or presence of any major medical or psychiatric illness
* Substantial medical condition that could create undue risk to the patient, could affect adherence with the study protocol or could undesirably affect study outcomes
Locations (76)
  • Altamonte Springs, Florida, United States
  • Coral Springs, Florida, United States
  • Yerevan, Armenia
  • Yerevan, Armenia
  • Yerevan, Armenia
  • Banja Luka, Bosnia and Herzegovina
  • Bihać, Bosnia and Herzegovina
  • Sarajevo, Bosnia and Herzegovina
  • Sarajevo, Bosnia and Herzegovina
  • Tuzla, Bosnia and Herzegovina
  • Tallinn, Estonia
  • Münster, Germany
  • Chandigarh, India
  • Gurugramam, India
  • Kochi, India
  • Lucknow, India
  • New Delhi, India
  • New Delhi, India
  • Punjābi Bāgh, India
  • Raipur, India
  • Lima, Peru
  • Katowice, Poland
  • Katowice, Poland
  • Katowice, Poland
  • Lublin, Poland
  • Lublin, Poland
  • Oświęcim, Poland
  • Plewiska, Poland
  • Poznan, Poland
  • Warsaw, Poland
  • + 46 more on CT.gov